This HTML5 document contains 78 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00462/identifier/wikipedia/
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00462/identifier/pharmgkb/
n10http://linked.opendata.cz/resource/drugbank/company/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00462/identifier/pubchem-compound/
n8http://linked.opendata.cz/resource/drugbank/dosage/
n9http://linked.opendata.cz/resource/drugbank/mixture/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00462/identifier/kegg-drug/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00462/identifier/pubchem-substance/
n18http://bio2rdf.org/drugbank:
n5http://linked.opendata.cz/resource/drugbank/drug/DB00462/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n14http://linked.opendata.cz/resource/drugbank/drug/DB00462/identifier/national-drug-code-directory/
n16http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n19http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n6http://linked.opendata.cz/ontology/drugbank/
n7http://linked.opendata.cz/resource/drugbank/property/
n4http://linked.opendata.cz/resource/drugbank/drug/DB00462/identifier/chemspider/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00462/identifier/chebi/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB00462
rdf:type
n6:Drug
n6:description
A muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors. [PubChem]
n6:dosage
n8:271B562D-363D-11E5-9242-09173F13E4C5 n8:271B562E-363D-11E5-9242-09173F13E4C5
n6:group
approved
n6:indication
Used as adjunctive therapy for the treatment of peptic ulcer. Also used to treat nausea and vomiting due to motion sickness.
n6:manufacturer
n10:271B5624-363D-11E5-9242-09173F13E4C5 n10:271B5625-363D-11E5-9242-09173F13E4C5
owl:sameAs
n16:DB00462 n18:DB00462
dcterms:title
Methylscopolamine bromide
adms:identifier
n4:3977 n5:DB00462 n11:PA164784032 n12:Methylscopolamine n13:61276 n14:60429-251 n20:23724781 n21:46506260 n22:D00715
n6:mechanismOfAction
Methscopolamine acts by interfering with the transmission of nerve impulses by acetylcholine in the parasympathetic nervous system (specifically the vomiting center). It does so by acting as a muscarinic antagonist.
n6:packager
n10:271B5622-363D-11E5-9242-09173F13E4C5 n10:271B5623-363D-11E5-9242-09173F13E4C5 n10:271B5621-363D-11E5-9242-09173F13E4C5
n6:synonym
Hyoscine methyl bromide Pamine Scopolamine methyl bromide Hyoscine Methobromide Scopolamine Methobromide (−)-scopolamine methyl bromide Methscopolamine bromide N-methylhyoscine bromide N-methylscopolammonium bromide (−)-scopolamine methobromide
n6:toxicity
Symptoms of a methscopolamine overdose include headache, nausea, vomiting, dry mouth, difficulty swallowing, blurred vision, dilated pupils, hot, dry skin, dizziness; drowsiness, confusion, anxiety, seizures, weak pulse, and an irregular heartbeat. In addition, a curare-like action may occur, i.e., neuromuscular blockade leading to muscular weakness and possible paralysis.
n6:mixture
n9:271B561F-363D-11E5-9242-09173F13E4C5 n9:271B5620-363D-11E5-9242-09173F13E4C5
n6:IUPAC-Name
n7:271B5633-363D-11E5-9242-09173F13E4C5
n6:InChI
n7:271B5639-363D-11E5-9242-09173F13E4C5
n6:Molecular-Formula
n7:271B5638-363D-11E5-9242-09173F13E4C5
n6:Molecular-Weight
n7:271B5635-363D-11E5-9242-09173F13E4C5
n6:Monoisotopic-Weight
n7:271B5636-363D-11E5-9242-09173F13E4C5
n6:SMILES
n7:271B5637-363D-11E5-9242-09173F13E4C5
n6:Water-Solubility
n7:271B5631-363D-11E5-9242-09173F13E4C5 n7:271B5649-363D-11E5-9242-09173F13E4C5
n6:logP
n7:271B5632-363D-11E5-9242-09173F13E4C5 n7:271B564B-363D-11E5-9242-09173F13E4C5 n7:271B562F-363D-11E5-9242-09173F13E4C5
n6:logS
n7:271B5630-363D-11E5-9242-09173F13E4C5
n6:H-Bond-Acceptor-Count
n7:271B563F-363D-11E5-9242-09173F13E4C5
n6:H-Bond-Donor-Count
n7:271B5640-363D-11E5-9242-09173F13E4C5
n6:InChIKey
n7:271B563A-363D-11E5-9242-09173F13E4C5
n6:Polar-Surface-Area--PSA-
n7:271B563B-363D-11E5-9242-09173F13E4C5
n6:Polarizability
n7:271B563D-363D-11E5-9242-09173F13E4C5
n6:Refractivity
n7:271B563C-363D-11E5-9242-09173F13E4C5
n6:Rotatable-Bond-Count
n7:271B563E-363D-11E5-9242-09173F13E4C5
n6:absorption
Poorly and unreliably absorbed, total absorption is 10-25%.
n6:affectedOrganism
Humans and other mammals
n6:caco2-Permeability
n7:271B564C-363D-11E5-9242-09173F13E4C5
n6:casRegistryNumber
155-41-9
n6:category
n6:containedIn
n19:271B562C-363D-11E5-9242-09173F13E4C5 n19:271B562A-363D-11E5-9242-09173F13E4C5 n19:271B562B-363D-11E5-9242-09173F13E4C5 n19:271B5628-363D-11E5-9242-09173F13E4C5 n19:271B5629-363D-11E5-9242-09173F13E4C5 n19:271B5626-363D-11E5-9242-09173F13E4C5 n19:271B5627-363D-11E5-9242-09173F13E4C5
n6:Bioavailability
n7:271B5645-363D-11E5-9242-09173F13E4C5
n6:Ghose-Filter
n7:271B5647-363D-11E5-9242-09173F13E4C5
n6:MDDR-Like-Rule
n7:271B5648-363D-11E5-9242-09173F13E4C5
n6:Melting-Point
n7:271B564A-363D-11E5-9242-09173F13E4C5
n6:Number-of-Rings
n7:271B5644-363D-11E5-9242-09173F13E4C5
n6:Physiological-Charge
n7:271B5643-363D-11E5-9242-09173F13E4C5
n6:Rule-of-Five
n7:271B5646-363D-11E5-9242-09173F13E4C5
n6:Traditional-IUPAC-Name
n7:271B5634-363D-11E5-9242-09173F13E4C5
n6:pKa--strongest-acidic-
n7:271B5641-363D-11E5-9242-09173F13E4C5
n6:pKa--strongest-basic-
n7:271B5642-363D-11E5-9242-09173F13E4C5